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BACKGROUND: Putative breast cancer stem cells might express surface markers such as aldehyde dehydrogenase 1 (ALDH1) and
BMI-1 proteins. The aim of this study was to explore the expression of these proteins in breast cancers from an African population
and their associations with the basal-like phenotype (BLP) and other molecular characteristics.
METHODS: We analysed 192 paraffin-embedded breast carcinoma samples by tissue microarrays and immunohistochemical methods.
RESULTS: In total, 88 tumours (48%) expressed ALDH1, whereas 46 (25%) expressed BMI-1 protein. Expression of ALDH1 was
associated with high histological grade (Po0.0005), high mitotic count (Po0.0005), high nuclear grade (Po0.0005), oestrogen
receptor (ER) negativity (Po0.0005), progesterone receptor (PR) negativity (P¼0.009), p53 expression (P¼0.034), cytokeratin 5/6
positivity (P¼0.008), epidermal growth factor receptor (EGFR) expression (P¼0.015) and the BLP (Po0.0005), whereas it was
inversely associated with BMI-1 staining (P¼0.009). On the other hand, BMI-1 expression was associated with low histological grade
(P¼0.004) and ER positivity (P¼0.001).
CONCLUSION: There was a high prevalence of ALDH1 expression among breast carcinomas and associations with basal markers and
features of aggressive tumours. Studies are required to elucidate the importance of these findings for improved understanding of
breast cancer biology.
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Human breast cancers have been reported to contain a sub-
population of cancer cells similar to epithelial stem cells
(Hamburger and Salmon, 1977; Al-Hajj et al, 2003; Abraham
et al, 2005). These cells have the ability to self-renew and undergo
differentiation to phenotypically diverse populations of tumour
cells (Al-Hajj et al, 2003). It has been suggested that cancer stem
cells drive the growth and spread of malignant tumours (Al-Hajj
et al, 2003), and the stem cell hypothesis might have important
implications for clinical management (Ginestier et al, 2007;
Tanei et al, 2009).
The molecular diversity and subclassification of breast cancers
have been reported in several studies during recent years
(Perou et al, 2000; Sorlie et al, 2003; Rakha et al, 2008). Five tumour
subgroups with different prognosis and response to adjuvant
therapy have been identified. Of these, the basal-like and HER2
subtypes are of particular interest as both have a poor prognosis
(Sorlie et al, 2001; Yang et al, 2007). The basal-like phenotype
(BLP) is characterised by the expression of basal cell markers,
and it overlaps with the triple-negative phenotype (TNP;
ER /PR /HER2 ) (Tischkowitz et al, 2007). It was reported that
basal-like and BRCA1-associated breast carcinomas, which are also
related (Foulkes et al, 2003) were both enriched with CD44þ/
CD24  candidate stem cells (Honeth et al, 2008), and BRCA1 has
been suggested to represent a stem cell regulator (Foulkes, 2004).
Previous studies indicate that stem cell-like populations in
breast tissue are characterised by the expression of aldehyde
dehydrogenase 1 (ALDH1), and breast cancer stem cells were
isolated on the basis of increased ALDH1 expression (Ginestier
et al, 2007). Thus, in the breast, expression of ALDH1 is considered
to be a marker of both normal and malignant stem and progenitor
cells (Ginestier et al, 2007). In established breast cancers, ALDH1
expression has been associated with poor clinical outcome
(Ginestier et al, 2007) and resistance to chemotherapy (Sladek
et al, 2002; Tanei et al, 2009). Furthermore, studies have indicated
that human breast cancers and cell lines contain a sub-population
of cells characterised by CD44þ/CD24
 /low/Lin  cell surface
markers, and a partial overlap between CD44þ/CD24
 /low/Lin 
and ALDH1-positive populations was reported (Al-Hajj et al, 2003;
Ginestier et al, 2007; Fillmore and Kuperwasser, 2008). It is
noteworthy that putative cancer stem cells expressing the
combined CD44þ/CD24
 /low/ALDH1þ phenotype showed an
especially high tumourigenic capacity, being able to form tumours
from as few as 20 cells (Ginestier et al, 2007).
The importance of BMI-1, a transcriptional repressor of the
polycomb group of transcription factors (Alkema et al, 1993) and a
key regulator of self-renewal in both normal and malignant stem
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scells (Liu et al, 2006), has been more controversial. Still, BMI-1 has
been linked to mammary carcinogenesis in some previous studies
(Dimri et al, 2002; Datta et al, 2007). Although some find BMI-1
expression to be associated with a favourable prognosis (Kim et al,
2004; Arnes et al, 2008; Choi et al, 2009), others have reported the
opposite (Glinsky et al, 2005; Silva et al, 2007).
Breast cancers in African populations and among African
Americans seem to be more aggressive than breast cancers in
Caucasians (Ikpatt et al, 2002; Jones et al, 2004), and better insight
about differences in tumour characteristics (Porter et al,2 0 0 4 ;
Fregene and Newman, 2005; Morris et al,2 0 0 7 ;B i r det al, 2008) may
suggest strategies to improve clinical management among Africans.
I ng e n e r a l ,t h e r ei ss o m ee v i d e n c et hat the limitation of chemotherapy
and radiation treatment may be associated with the inability to target
breast cancer stem cells (Phillips et al, 2006; Fillmore and
Kuperwasser, 2008; Li et al, 2008; Tanei et al, 2009), and the efficacy
of HER2 inhibitors may relate to their influence on stem cell
populations in HER2-positive tumours (Korkaya et al, 2008).
On this background, the purpose of our study was to examine
the expression of candidate stem cell markers ALDH1 and BMI-1
in breast cancer in relation to basal-like markers, other molecular
features and clinicopathological phenotype. These markers were
examined in tumours from an African population in which breast
cancer is assumed to be more aggressive and also associated with
frequent basal-like differentiation (Nalwoga et al, 2007). In these
populations, early diagnosis and effective treatment is especially
challenging (Gakwaya et al, 2008).
MATERIALS AND METHODS
Patient series
Cases of primary breast carcinoma with available and technically
suitable archival paraffin blocks from the period 1990 to 2002 were
identified in the Kampala Cancer Registry at the Department of
Pathology, Makerere University College of Health Sciences,
Kampala (Uganda). The Registry serves an area of about
1914km
2, which comprises of Kampala with neighbouring urban
and semi-urban areas (Gondos et al, 2005) and an estimated
population of 1.7 million in 2002 (Population Council, 2004). The
population of females 415 years of age is about 530000. The
Baganda from the Central region is the largest ethnic group in the
county, but other ethnic groups are represented. The registry
methods of collecting data and results have been previously
reported (Wabinga et al, 1993).
Altogether, 192 cases were included in the study, and 87 other
cases with inadequate tissue available were excluded. Clinical
information was obtained from the histology reports. The mean
age was 46.2 years (range 18–80 years). Duration of symptoms as
reported by 127 patients at the time of presentation was 17.1
months on average (median 9 months; range 0.5–108 months).
The cutoff point for long duration was 9 months (median value).
Stage of disease at the time of diagnosis was available in only 22
patients; the majority (n¼12) were in stage 4, 8 (36%) were in
stage 3, whereas stage 1 and 2 contributed 9%. All cases were
re-examined histologically (by HN and JBA) and classified according
to the World Health Organisation (Tavassoli and Devilee, 2003)
and histological grading was performed in accordance with the
Nottingham criteria (Elston and Ellis, 1991). Nuclear grade and
mitotic count was also recorded as separate variables according to
the same criteria. The permission to conduct this research was
obtained from the Research Ethical Committee at Makerere
University College of Health Sciences.
Tissue microarray
The tissue microarray (TMA) technique has been validated in
several studies (Camp et al, 2000). TMA was performed on 192
cases using archival tissues of invasive breast carcinomas
according to Kononen et al (1998). Representative tumour areas
were identified on haematoxylin and eosin-stained slides, and a
minimum of three tissue cylinders (diameter 1mm) were punched
from selected areas of the donor block and mounted into the
recipient paraffin block using a custom-made precision instrument
(Beecher Instruments, Silver Spring, MD, USA). Sections of 5mm
thickness of the resulting TMA blocks were made by standard
technique.
Immunohistochemistry
The TMA sections were stained with antibodies as shown in
Table 1. Sections were deparaffinised in xylene, rehydrated
through a series of graded alcohols and rinsed in distilled water.
Antigen retrieval based on microwave oven heating with retrieval
buffer at 750W for 10min followed by 350W for 15min (an extra
5min at 350W was added for p53, p63 and BMI-1, and 15min for
Ki-67) was used for all antibodies, except epidermal growth factor
receptor (EGFR) for which proteinase predigestion for 10min was
applied. Tris–EDTA pH 9.0 retrieval buffer was used for all
markers except ALDH1 for which citrate buffer pH 6.0 was used.
Sections were allowed to cool at room temperature for 20min and
then thoroughly rinsed in buffer solution and placed in the Dako
Autostainer (DakoCytomation, Glostrup, Denmark) for staining.
Endogenous peroxidase activity was blocked by incubating
sections with 0.03% hydrogen peroxidase containing sodium azide
for 5min, followed by rinsing with buffer solution. Then sections
Table 1 Immunohistochemical staining procedures
Biomarker Antibody Clone Dilution Incubation time (min)
ER MMA oestrogen receptor-a 1D5 1:50 30
PR MMA progesterone receptor PgR 636 1:150 30
HER2 RA c-erbB-2 oncoprotein Polyclonal 1:500 60
Ki-67 MMA Ki-67 antigen MIB-1 1:50 60
p53 MMA p53 protein DO-7 1:1000 60
p63 MMA p63 protein A4A 1:300 30
CK 5/6 MMA cytokeratin 5/6 D5/16 B4 1:200 30
P-cadherin P-cadherin purified MA 56 1:400 60
EGFR Mouse anti-EGFR 31G7 1:30 30
c-kit RA CD117, c-kit Polyclonal 1:200 30
ALDH1 Purified M anti-ALDH 44 1:250 60
BMI-1 Anti-BMI-1 6C9 1:1 60
Abbreviations: MMA¼monoclonal mouse antihuman; MA¼mouse antihuman; RA¼rabbit antihuman; M¼mouse; ER¼oestrogen receptor; PR¼progesterone receptor;
EGFR¼epidermal growth factor receptor; ALDH1¼aldehyde dehydrogenase 1; CK¼cytokeratin.
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swere incubated with specific antibodies at room temperature.
Regarding antibodies, P-cadherin and ALDH1 were obtained from
BD Biosciences (Oxford, UK), mouse anti-EGFR was obtained
from Zymed Laboratories (San Francisco, CA, USA), and BMI-1
was produced as previously described (Arnes et al, 2008), whereas
all other antibodies were obtained from DakoCytomation A/S. All
antigens were detected by the DakoCytomation EnVisionþ
system-horseradish peroxidase for 30min, except BMI-1 for which
the CSA II kit (DakoCytomation) was used. After rinsing the
sections in buffer solution, we developed the peroxidase by
incubating with freshly prepared 3,30-diaminobenzidine chromo-
gen solution for 10min. Sections were then rinsed in distilled water
and counterstained with Meyer’s haematoxylin. Cases of breast or
colonic carcinoma previously known to be positive for the markers
studied were used as positive controls. For c-kit, a gastrointestinal
stromal tumour (GIST) was used.
Evaluation of staining
Tumours without interpretable cores (2.6–4.7%) because of
insufficient tumour tissue were omitted from the analysis. A total
of 183–187 cases could be evaluated for the various markers. The
oestrogen receptor (ER), progesterone receptor (PR), HER2, EGFR,
Ki-67, p53, p63, cytokeratin (CK) 5/6, P-cadherin, c-kit and BMI-1
were evaluated as previously described (Engelsen et al, 2006;
Stefansson et al, 2006; Arnes et al, 2008; Nalwoga et al, 2008).
Regarding ALDH1, cytoplasmic staining was evaluated, whereas
nuclear staining alone was considered nonspecific and was not
included in the analysis.
For BMI-1, a staining index (values 0–9) was determined by
multiplying the score for intensity of staining (none¼0, weak¼1,
moderate¼2 and strong¼3) with the score for proportion of
tumour cells stained (o10%¼1, 10–50%¼2, 450%¼3) (Arnes
et al, 2008). The majority of cases (75%) had staining index 0, and
therefore the cutoff was 0¼negative and 1–9¼positive. For
ALDH1, the median staining index was 2, and the cutoff point was
set at 0–2¼negative and 3–9¼positive. Ki-67 proliferative rate
was determined as previously described (Nalwoga et al, 2007). The
cutoff point for Ki-67 was set at 20.0% based on the median value
for this series.
Molecular subtypes
There is no consensus on how to define different molecular
subtypes of breast cancer by immunohistochemical markers, and
overlapping categories exist. We used criteria on the basis of this
literature (Carey et al, 2006; Yang et al, 2007; Sihto et al, 2008) for
subclassification into molecular subtypes. In accordance with
Carey et al (2006), we defined the luminal A (ERþ and/or PRþ,
HER2 ), luminal B (ERþ and/or PRþ, HER2þ), HER2þ
subtype (ER ,P R  , HER2þ) and the basal-like subtype (ER ,
HER2  and CK 5/6þ and/or EGFRþ) subgroups. Tumours
negative for all the five markers (ER, PR, HER2, CK 5/6 and EGFR)
were considered as unclassified. This definition for luminal B
tumours does not identify all luminal B tumours because only 30–
50% are HER2þ and the rest are classified with the luminal A. We
therefore merged luminal A and luminal B into the luminal
subtype. Further, in accordance with our previous studies, we
included P-cadherin staining in the definition of BLP (Nalwoga
et al, 2007; Arnes et al, 2008). Using the Arnes et al (2008) criteria,
we defined BLP profiles as follows: BLP1: concurrent ER , HER2 
and CK 5/6þ; BLP2: concurrent ER , HER2  and P-cadherinþ;
BLP3: concurrent ER , HER2  and EGFRþ; BLP4: concurrent
ER , HER2  and CK 5/6þ and/or EGFRþ; BLP5: concurrent
ER , HER2  and positivity for one or more basal markers
(CK 5/6, P-cadherin and EGFR). BLP4 is identical to the core basal
phenotype as defined by Nielsen et al (2004) and Tischkowitz et al
(2007).
Statistical analysis
Statistical analysis was performed using the SPSS version 15.0
software (SPSS Inc, Chicago, IL, USA). We examined the
association between ALDH1 and BMI-1 expression with other
tumour characteristics using w
2-test and Fisher’s exact test. The t-
test was used to detect the differences in average age between
groups. A P-value of o0.05 was considered significant for any
statistical test used.
RESULTS
In all, 88 tumours (48%) were positive for ALDH1, whereas 95
(52%) were negative for ALDH1 (Figure 1). The majority (62%) of
ALDH1-positive cases were high-grade ductal carcinomas. Alto-
gether, 40 cases (46%) showed staining in 410% of the tumour
cells, whereas 16 of 88 (18%) cases had a diffuse staining in X50%
of the tumour cells. Overall, the expression of ALDH1 seemed to be
evenly distributed throughout the tumour cell population,
although there were some cases with clusters of positively stained
cells within the diffuse pattern. The average percentage of stained
tumour cells in positive cases was 18%. Of the ALDH1-positive
tumours, 31% were of the luminal subtype (27.3% luminal A, 3.4%
luminal B), 31% had a basal-like subtype (core basal phenotype;
BLP4), 16% were in the HER2 subtype and 23% were in the
unclassified category. A majority (53%) of the ALDH1-positive
cases were triple-negative tumours.
Table 2 shows ALDH1 expression and associations with
clinicopathological characteristics. Patients with a shorter duration
of symptoms were more likely to express ALDH1 than those with
longer duration of symptoms (odds ratio 2.2; 95% confidence
interval 1.05–4.5, P¼0.036). The ALDH1 expression was
significantly associated with markers of poor prognosis, such as high
histological grade, high mitotic counts, high nuclear grade, ER
negativity, PR negativity, and p53 expression. No associations were
Figure 1 Positive (A) and negative (B) expression of aldehyde
dehydrogenase 1 (ALDH1) protein in tumour cells of breast carcinomas
(both  400 magnification).
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sfound between ALDH1 expression and HER2 status, p63 or c-kit
positivity.
As shown in Table 3, CK5/6 was positive in 15%, P-cadherin in
27% and EGFR in 20% of all cases. One or more of these were
positive in 33% of the cases (61 of 185). A total of 86 tumours
(46%) were of the luminal subtypes (42%, luminal A, 4% luminal
B), 22% (41 of 186) had a basal-like subtype, the HER2 subtype
contributed 12% (23 of 186), and 19% (36 of 186) were in the
unclassified group. Regarding the different BLP profiles, 15% (27
of 186) were BLP1, 22% (41 of 187) were BLP2, 17% (31 of 186)
were BLP3, 22% (41 of 186) were BLP4 (core basal phenotype) and
26% (49 of 186) were BLP5. All tumours in the different BLP
profiles were triple negative in this series. A majority of the triple-
negative tumours showed basal-like differentiation; 53% (41 of 77)
had a core basal profile (BLP4), whereas 64% (49 of 77) of the TNP
tumours had positive expression of at least one of the three basal
markers (CK5/6, P-cadherin, EGFR) combined with ER– and
HER2–, corresponding to the BLP5 profile.
Table 3 also shows the relationship between ALDH1 positivity
and molecular subtypes of breast cancer. The ALDH1 expression
Table 2 ALDH1 expression and associations with clinicopathological
features and molecular characteristics
Variable
ALDH1
negative
(n;% ) ;
n¼95
ALDH1
positive
(n;% ) ;
n¼88
OR
(95% CI) P-value
Age in years
o50 52 (52) 48 (48) 1.0
X50 37 (49) 38 (51) 1.1 (0.6–2.0) NS
Duration of symptoms
p9 months 26 (41) 37 (59) 1.0
49 months 35 (60) 23 (40) 0.5 (0.2–1.0) 0.036
Histological type
Ductal 82 (51) 79 (49) 1.0
Others 13 (62) 8 (38) 1.6 (0.6–4.0) NS
Histological grade
Grade 1 20 (87) 3 (13) 1.0
Grade 2 38 (59) 26 (41) 4.6 (1.2–16.9) 0.016
Grade 3 37 (39) 58 (61) 10.5 (2.9–37.6) 0.000
Nuclear grade
Grade 1 18 (72) 7 (28) 1.0
Grade 2 48 (63) 28 (37) 1.5 (0.6–4.0) NS
Grade 3 29 (36) 52 (64) 4.6 (1.7–12.3) 0.001
Mitotic count
0–6 31 (71) 13 (29) 1.0
7–13 29 (67) 14 (33) 1.5 (0.5–2.9) NS
413 35 (37) 60 (63) 3.3 (1.9–8.8) 0.000
Ki-67
Low (o20%) 50 (57) 38 (43) 1.0
High (X20%) 45 (47) 50 (53) 1.4 (0.8–2.6) NS
p53
Low SI (0–4) 73 (57) 55 (43) 1.0
High SI (44) 22 (40) 33 (60) 2.0 (1.05–4.8) 0.034
ER
Positive 48 (69) 22 (31) 1.0
Negative 47 (42) 66 (58) 3.1 (1.6–5.7) 0.000
PR
Positive 35 (67) 17 (33) 1.0
Negative 60 (46) 71 (54) 2.4 (1.2–4.7) 0.009
HER2
Negative 82 (54) 71 (46) 1.0
Positive 13 (43) 17 (57) 1.5 (0.7–3.3) NS
Abbreviations: ALDH1¼aldehyde dehydrogenase 1; OR¼odds ratio; CI¼confidence
interval; NS¼not significant; SI¼staining index; ER¼oestrogen receptor; PR¼pro-
gesterone receptor.
Table 3 ALDH1 expression and associations with basal markers,
molecular subtypes, BMI-1, c-kit and p63 expression
Variable
ALDH1
negative
(n; %);
n¼95
ALDH1
positive
(n;% ) ;
n¼88
OR
(95% CI) P-value
CK 5/6
Negative 86 (56) 68 (44) 1.0
Positive 8 (29) 20 (71) 3.2 (1.3–7.6) 0.008
P-cadherin
Negative 75 (56) 58 (44) 1.0
Positive 20 (40) 30 (60) 1.9 (1.0–3.8) 0.048
EGFR
Negative 81 (56) 64 (44) 1.0
Positive 12 (33) 24 (67) 2.5 (1.1–5.4) 0.015
BLP1
Absent 86 (56) 69 (44) 1.0
Present 8 (30) 19 (70) 2.9 (1.2–7.4) 0.013
BLP2
Absent 80 (56) 62 (44) 1.0
Present 15 (37) 26 (63) 2.2 (1.1–4.6) 0.026
BLP3
Absent 84 (56) 67 (44) 1.0
Present 10 (32) 21 (68) 2.6 (1.2–6.0) 0.018
BLP4 (CBP)
Absent 80 (57) 61 (43) 1
Present 14 (34) 27 (66) 2.5 (1.2–5.2) 0.011
BLP5
Absent 77 (58) 56 (42) 1.0
Present 17 (35) 32 (65) 2.6 (1.3–5.1) 0.005
TNP
No 65 (61) 41 (39) 1.0
Yes 30 (39) 47 (61) 2.5 (1.4–4.5) 0.003
Molecular subtype
Luminal 56 (68) 27 (32) 1.0
HER2 8 (36) 14 (64) 3.6 (1.4–9.7) 0.008
Basal-like 14 (34) 27 (66) 4.0 (1.8–8.8) 0.000
Unclassified 16 (44) 20 (56) 2.6 (1.2–5.8) 0.018
c-kit
Negative 91 (52) 84 (48) 1.0
Positive 4 (50) 4 (50) 1.1 (0.3–4.4) NS
p63
Negative 80 (53) 71 (47) 1.0
Positive 15 (47) 17 (53) 1.3 (0.6–2.7) NS
BMI-1
Negative 64 (46) 74 (54) 1.0
Positive 31 (69) 14 (31) 0.4 (0.2–0.8) 0.009
Abbreviations: ALDH1¼aldehyde dehydrogenase 1; OR¼odds ratio; CI¼confi-
dence interval; NS¼not significant; EGFR¼epidermal growth factor receptor;
CK¼cytokeratin; CBP¼core basal phenotype; TNP¼triple-negative phenotype.
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swas significantly associated with molecular subtype and BLP
profiles as defined in this paper, as well as with TNP and individual
basal markers CK 5/6 and EGFR. Thus, the BLP, the HER2
subgroup and the unclassified category were more likely to express
ALDH1 than the luminal subtypes.
In all, 46 tumours (25%) were positive for BMI-1 staining. The
majority of cases (61%) were of the luminal subtype (54.3%
luminal A, 6.5% luminal B), whereas the basal-like category
contributed 22%, 11% were in the HER2 subgroup and 7% were
unclassified. In total, 13 tumours (28%) were triple negative. The
BMI-1 positivity was mostly associated with features of good
prognosis, such as low histological grade (P¼0.011), low mitotic
counts (P¼0.010) and ER positivity (P¼0.001). Further, BMI-1
expression was inversely associated with the TNP (P¼0.037) and
with ALDH1 positivity (P¼0.009). Tumours in the luminal
subtype (odds ratio 5.4; 95% confidence interval 1.05–19.2,
P¼0.005) were more likely to express BMI-1 than unclassified
tumours. No association was found between BMI-1 expression and
the other subtypes, the basal markers such as CK5/6, P-cadherin,
EGFR, and the BLP profiles.
DISCUSSION
In this study, our aim was to explore the expression of candidate
stem cell markers ALDH1 and BMI-1 in breast cancers from an
African population and their possible associations with BLP and
other molecular markers. We found that ALDH1 expression was
associated with features of aggressive tumours such as high
histological grade, high nuclear grade, high mitotic count, p53
expression and ER/PR negativity. In addition, ALDH1 expression
was associated with a short duration of symptoms. Thus, ALDH1
status might represent an indicator of aggressive breast cancer
(Ginestier et al, 2007; Morimoto et al, 2009). In support of this,
others have suggested that the amount of cancer stem cells within
breast tumours may correspond to the risk of distant metastases
(Abraham et al, 2005; Glinsky et al, 2005).
It has been observed that basal-like breast cancers might be
enriched with CD44þ/CD24  cells (Honeth et al, 2008), and an
overlap between CD44þ/CD24  cells and ALDH1-positive cell
populations were described (Ginestier et al,2 0 0 7 ) .M o r e o v e r ,t h e
CD44þ/CD24 /ALDH1þ phenotype identified a highly tumouri-
genic cell population that was able to form tumours from as few as 20
cells. Our results showed that ALDH1 was significantly associated
with the basal-like subtype and different BLP profiles, as well as with
individual basal markers CK 5/6 and EGFR, similar to what others
have reported (Ginestier et al, 2007). To speculate, our findings might
be related to the aggressive behaviour and therapy resistant features
of the basal-like breast cancer subtype (Sorlie et al,2 0 0 1 ;B a n e r j e e
et al, 2006; Fillmore and Kuperwasser, 2008; Li et al, 2008). Moreover,
we found a significant association between ALDH1 expression and
the triple-negative tumours, a group whose poor prognosis has been
widely reported (Dent et al, 2007).
Our findings indicate a higher frequency of ALDH1 expression
(48%) in this series of breast cancer from an African population,
compared with 19 and 30% in two different Caucasian populations
described by Ginestier et al (2007). We also found more extensive
staining in positive cases (Ginestier et al, 2007). Further, in
comparison with data derived from breast tumours in Caucasian
and Asian populations (Ginestier et al, 2007; Morimoto et al, 2009;
Tanei et al, 2009) regarding ALDH1 positivity rate in tumours with
similar characteristics (histological grade, ER, HER2, Ki-67), we
observed that tumours from our present series stained in a higher
percentage of cases in most poor prognosis categories (such as
high histological grade, ER-negative cases, HER2-negative cases,
tumours with high Ki-67 expression). Hence, apart from
methodological discrepancies, biological differences might be
present when comparing breast cancers from African and
Caucasian populations (Elledge et al, 1994; Ikpatt et al, 2002;
Jones et al, 2004; Porter et al, 2004). In line with this, a poorer
outcome has been observed in African and African-American
patients (Wojcik et al, 1998; Ikpatt et al, 2002) when compared
with breast cancers among Caucasians, with differences in the
spectrum of tumour characteristics and prognostic features such as
the presence of tumour necrosis, low ER positivity rate, high
HER2-positive rate, and a high frequency of basal-like features
(Mbonde et al, 2001; Ikpatt et al, 2002; Carey et al, 2006; Nalwoga
et al, 2006, 2007; Morris et al, 2007; Bird et al, 2008).
In contrast to our findings on ALDH1, the expression of BMI-1,
another candidate stem cell marker (Arnes et al, 2008), was
inversely associated with ALDH1 and related to features of good
prognosis, such as low histological grade, low mitotic count, ER
positivity and absence of TNP (Kim et al, 2004; Choi et al, 2009).
This is in line with our recent studies of breast cancer (Arnes et al,
2008) and other tumours (Bachmann et al, 2008; Engelsen et al,
2008). The frequency of BMI-1 expression (25%) was lower than
those found in other studies (43–62%) (Kim et al, 2004; Arnes
et al, 2008; Choi et al, 2009). Others have found different results,
BMI-1 expression being associated with more aggressive tumours
(Glinsky et al, 2005; Silva et al, 2007). In addition, Glinsky et al
(2005) found that expression of a BMI-1-driven 11 gene signature
was associated with risk of metastases in breast carcinoma. The
explanation for this inverse relationship is not known.
In conclusion, we observed a high prevalence of ALDH1 staining
in this series of invasive breast carcinomas from Uganda.
Expression of ALDH1 was significantly associated with a BLP
and with features of aggressive tumours. Assessment of ALDH1
expression might help to identify a high-risk (Sreerama and
Sladek, 1997) subgroup of breast cancers in this population. More
studies are required to elucidate the possible significance of these
stem cell markers in breast cancer patients.
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